Patent · US Active

Use of fusion protein

US9593151B2 · kind B2 · utility

1Cited by

3References

12Claims

0Family size

Assignee

East China University of Science and Technology · CN

Inventors

Changsheng Liu · State College, US
Wanli Xing · Beijing, CN
Jing Wang · Beijing, CN
Jiangchao Qian · Shanghai, CN
Jing Liang · Princeton, US

Key dates

Filing date	Dec 5, 2013
Grant date	Mar 14, 2017
Priority date	—
Expiry date	Dec 5, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is the use of a fusion protein in drugs for stimulating differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, or drugs for proliferation of granulocyte hematopoietic progenitor cells. The fusion protein has a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. The drugs can be used for the prevention and/or treatment of (i) hematopoietic dysfunction caused by chemotherapy, (ii) hematopoietic dysfunction caused by radiotherapy, or (iii) leukopenia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.